Abzena and BioXpress Therapeutics partner on biosimilars

Jonathan Goldman, MD, CEO of Abzena said: “We are delighted to enter a partnership with a company who share our commitment to producing biologics to positively impact patient lives"

Abzena, a partner research organisation for biologics and bioconjugates, and BioXpress Therapeutics, developer of monoclonal antibody (mAb) biosimilar therapeutics, have announced a partnership to support biosimilar development for third party customers.

The partnership is aimed to ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, through to clinical and commercial GMP manufacture.

Jonathan Goldman, MD, CEO of Abzena said: “We are delighted to enter a partnership with a company who share our commitment to producing biologics to positively impact patient lives particularly those who will benefit from access to lower cost biotherapeutics. This new integrated offering will provide our partners a de-risked approach to biosimilar development, all the way to clinical development and ultimately to the market.”

Gerrit Hagens, PhD, Director at BioXpress Therapeutics commented: “This partnership allows for a simplification of drug development timelines for the biosimilars market. The BioXpress Therapeutics and Abzena strengths are complementary and this partnership provides a flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”

Companies